Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 7/20 | 0.46 |
| ▸ | FPR3 | P25089 | 3/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24495119 | 1.00 | RORC (0.49) | RORCUSP30FPR2FPR3PDE4B | |
| SCHEMBL24495116 | 1.00 | RORC (0.49) | RORCUSP30FPR2FPR3PDE4B | |
| SCHEMBL19458918 | 0.90 | RORC (0.49) | RORCUSP30FPR2FPR3PDE4B | |
| SCHEMBL19458917 | 0.90 | RORC (0.49) | RORCUSP30FPR2FPR3PDE4B | |
| SCHEMBL19490839 | 0.90 | RORC (0.49) | RORCUSP30FPR2FPR3PDE4B | |
| SCHEMBL19459065 | 0.90 | RORC (0.49) | RORCUSP30FPR2FPR3PDE4B | |
| SCHEMBL4602756 | 0.89 | PDE4B (0.46) | RORCUSP30PDE4BGPR119TACR1 | |
| SCHEMBL26808070 | 0.89 | GPR119 (0.55) | RORCUSP30PDE4BGPR119TACR1 | |
| SCHEMBL16874803 | 0.89 | PDE4B (0.46) | RORCUSP30PDE4BGPR119TACR1 | |
| SCHEMBL3062563 | 0.89 | PDE4B (0.46) | RORCUSP30PDE4BGPR119TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552801-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250313565-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4522617-A1 | NEW INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119173518-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-3986566-A1 | NEW EGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993872-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113993591-A | Novel EGFR inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-112437774-A | Compound (I) | 豪夫迈·罗氏有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-3077387-B1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-20 | — | — | EP | disclosed |
| US-9562035-B2 | Benzamide derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-07 | — | — | US | disclosed |
| EP-3077387-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica, N.V. (BE) | 2016-10-12 | — | — | EP | disclosed |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-14 | — | — | US | disclosed |
| WO-2015084606-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A5 | RORC 458/4885USP30 4090/4885FPR2 2727/4885 |
| US-20250313565-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, ABCB11, CYP3A7 | RORC 319/4885USP30 3585/4885FPR2 3447/4885 |
| US-20160009688-A1 | BENZAMIDE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, FABP1, BCL3 | RORC 3624/4885USP30 3002/4885FPR2 2741/4885 |
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, ABCB11, CYP3A7 | RORC 319/4885USP30 3585/4885FPR2 3447/4885 |
| US-12552801-B2 | Indazole derivatives | EGFR, ABL1, ERBB3 | RORC 2206/4885USP30 2971/4885FPR2 2037/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | RORC 1111/4885USP30 3187/4885FPR2 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.